Please login to the form below

Not currently logged in

New data for Tecentriq in early-stage lung cancer

Roche’s PD-L1 blocker reduced the risk of disease recurrence and death for patients with stage 2-3a non-small cell lung cancer following surgery

Lung cancer is under the spotlight this time of year with two back-to-back oncology meetings, the European Society for Medical Oncology (ESMO) and World Conference on Lung Cancer (WCLC).

Roche has presented new data for its PD-L1 inhibitor Tecentriq (atezolizumab) at both events, adding to the body of evidence supporting the use of the monoclonal antibody in patients with early-stage non-small cell lung cancer (NSCLC).

Data presented at ESMO – and published simultaneously in the Lancet – confirms Tecentriq as the “first and only cancer immunotherapy to demonstrate positive Phase III results in the adjuvant lung cancer setting”, says Roche.

In the phase 3 IMpower010 study, treatment with Tecentriq following surgery and chemotherapy reduced the risk of disease recurrence or death by 34% in people with stage 2-3A NSCLC whose tumours expressed PD-L1 compared with best supportive care (BSC).

“Today, more than half of all people with early-stage NSCLC experience recurrence following surgery,” said Roche CMO, Levi Garraway. “IMpower010 shows how, for the first time, a cancer immunotherapy may help many of these patients live longer without their disease returning.”

Roche also released new real-world data that shows almost three-quarters of patients with early-stage NSCLC in the US did not receive adjuvant treatment even though clinical guidelines recommend that they do.

An extended analysis also suggested that the benefit from adjuvant Tecentriq was greater in people with a higher expression of PD-L1, although Roche stressed that the analysis was preliminary.

The data presented at WCLC was also from the IMpower010 study, and showed that treatment with Tecentriq benefited stage 2-3A NSCLC patients regardless of surgery types and adjuvant chemotherapy regimen.

Tecentriq has been given priority review by the US Food and Drug Administration and data is being tracked as part of the Real-Time Oncology Review pilot programme, which aims to find a new process that gets safe and effective treatments to patients as early as possible.

The FDA is expected to make a decision on whether to approve Tecentriq in this indication by early December.

Tecentriq is already approved in five lung cancer indications and Roche has an extensive development programme including multiple ongoing and planned phase 3 studies in lung, genitourinary, skin, breast, gastrointestinal, gynaecological, and head and neck cancers.

Article by
Hugh Gosling

21st September 2021

From: Research, Regulatory, Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
Senior Analytics Specialist joins Research Partnership...